With scalable infrastructure, proprietary intellectual property, and growing demand across multiple sectors, NEXGEL is well-positioned to lead innovation in topical delivery systems. The company generates revenue from branded over-the-counter (OTC), private label, and Contract Development and Manufacturing Organization (CDMO) channels, providing flexibility, scale, and reduced market dependence. The Celularity transaction establishes NEXGEL as an emerging platform in regenerative medicine through the formation of BioNX Surgical, a dedicated division focused on advanced biomaterials for tendon repair, soft tissue reconstruction, and bone regeneration.
Cyborg Score Rationale
The Celularity acquisition is expected to approximately triple NEXGEL's annual revenue to about $35 million and make the company immediately profitable upon closing. Strong fundamentals include established, reimbursed products with commercial traction, but significant dilution risk from convertible debt and warrant structures present near-term shareholder challenges.
Top Insights
The Celularity acquisition signed in March 2026 is expected to triple revenue to approximately $35 million and achieve immediate profitability upon closing.
The acquired portfolio includes 6 established products with over a decade of clinical use and existing reimbursement coverage, positioning the company for accelerated commercial expansion and near-term revenue scale.
NEXGEL offers contract development and packaging services through its CG Converting & Packaging subsidiary, allowing it to serve a wide range of clients across healthcare and consumer markets.
Significant convertible debt of $6.9 million, warrants for 5.75 million shares, and milestone payments of up to $17.5 million create substantial potential dilution and future financial commitments.
Named Competitors
Smith & Nephew — Advanced wound care and regenerative medicine products
Organogenesis — Regenerative medicine and advanced wound care
Integra LifeSciences — Regenerative biomaterials for surgery and wound care
3M Health Care — Wound care and medical supplies
Recent Developments
(April 2026) Closed $13.3 million acquisition of Celularity's regenerative biomaterials portfolio and launched BioNX Surgical division with $5.5 million financing from Sequence LifeScience
(March 2026) Signed definitive agreement to license and acquire six commercial-stage regenerative biomaterial products from Celularity
(May 2024) Acquired Silly George® beauty brand, expected to add $2 million in annual revenue
(February 2026) Raised $1.797 million tied to potential acquisition with another $14.869 million possible
Open the full interactive NEXGEL, INC. report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.